NCT05092139Completed
Endovascular treatmenT for Acute Ischemic Stroke in China (DETECT2-China)
enDovascular trEatmenT for acutE isChemic sTroke in China (DETECT2-China): a Prospective, National, Multi-center, Registry Study
Source: ClinicalTrials.gov · Last updated 18 Mar 2025
Brief summary (registry, in English)
This is a prospective real world registry study, aiming to explore the effectiveness and safety of endovascular treatment of acute ischemic stroke in a Chinese population.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 3000 (actual)
- First submitted
- 13 Oct 2021
- Start date
- Jan 2022
- Primary completion date
- Jan 2025
- Lead sponsor
- General Hospital of Shenyang Military Region
- Diseases
- Stroke
- NCT number
- NCT05092139
What you commit to
- Study type: Observational
- Participants enrolled: 3000
- From Jan 2022 to the primary completion date, Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Other serious illness that would confound the clinical outcome at 90 days;
- Other unsuitable conditions judged by the investigator
Other
- Prestroke mRS≥3;
- Unavailable neuroimaging data;
Who the study is looking for
- Age: ≥ 18;
- Ischemic stroke confirmed by head CT or MRI;
- Patients receiving endovascular treatment;
- First ever stroke or pre-stroke mRS≤2;
- signed informed consent.
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hui-Sheng Chen Coordinator of this site? Confirm its status | Shenyang | China | Unknown status |
Related publications
- Association of the neutrophil percentage-to-albumin ratio after endovascular treatment and 3-month clinical outcomes.Front Neurol · 2026 · PMID 41766997
This page is information, not medical advice. Discuss any trial with your doctor.